Additionally, analysis of PBMCs from MS patients by Hallal-longo et al. demonstrated that patients treated with IFN-β had higher expression of intracellular CTLA-4, which culminated in diminished proliferative response to MBP and myelin and enhanced lymphocyte apoptosis [166]. This evidence concerns the gene IFNB1 and myeloid sarcoma.